BAY 2666605 (C09-1113-857)

BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC 50 s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135)In VitroBAY 2666605 (example 135) has anticancer effects, potently inhibit brain cancer(especially glioma, more specifically glioblastoma, astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML(especially erythroleucemia), lung cancer(especially NSCLC adenocarcinoma and SCLC), skin cancer(especially melanoma), oesophagus cancer (especially squamous cell carcinoma), ovarian cancer, (especially teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoBAY 2666605 (5 mg/kg; p.o; twice daily) teatment shows anti-tumor efficacy in murine xenotransplantation models of human cancer . MCE has not independently confirmed the accuracy of these methods. They are for reference only.IC50& Target:PDE3A 87 nM (IC 50 ) PDE3B 50 nM (IC 50 ). Specification: 10mM in DMSO Molecular Formula: C17H12F4N2O2 Molecular Weight: 352.28